Novo Nordisk Faces Class-Wide NAION Label Change as Liver Data and ObesityWeek Lineup Take Shape
Published on 11/10/2026 at 08:51 | Editorial boerse-global.de
US regulators have ordered Novo Nordisk to add a warning about a possible heightened risk of the rare eye condition NAION to the prescribing information for Ozempic and Wegovy. The FDA issued the instruction yesterday, and it applies to the entire GLP-1 drug class rather than to Novo's products alone.
The agency's directive extends to Eli Lilly's Mounjaro and Zepbound, according to Reuters, meaning the two dominant players in the obesity and diabetes market face the same labeling requirement. The warning must appear in the section covering warnings and precautions.
NAION — non-arteritic anterior ischemic optic neuropathy — can disrupt the blood supply to the optic nerve and trigger sudden, painless vision loss. The damage may be permanent and typically affects one eye. No treatment is known to reverse the loss.
Patients who experience sudden vision loss, blurred sight or blind spots are advised by the FDA to seek medical help at once. Those diagnosed with NAION should discuss their medication with a physician, and the agency cautions against stopping treatment on their own.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Fifteen Cases Across 126 Trials
The warning rests on a broad evidence base. The FDA reviewed 126 clinical trials involving more than 134,000 patients and identified 15 probable NAION cases in total. Among GLP-1 users the incidence came to 6.4 cases per 100,000 patient-years, against 3.8 cases in comparator groups.
A supplementary FDA analysis in adults with type-2 diabetes produced results that varied with the comparison drug. Against DPP-4 inhibitors, an elevated risk emerged. Against SGLT-2 inhibitors, the difference was not statistically significant — a reminder that the safety picture depends on which treatment arms are set side by side.
BMO analysts view the risk to Novo Nordisk and Eli Lilly as limited given how uncommon the condition is. That assessment offers some support to Novo, provided the low frequency holds up in further research.
Investors appeared unruffled. The stock closed yesterday with a 1.9% gain, holding firm on the day the order was announced. Ahead of today's session it was up 0.4% in premarket trading, though no causal link between the safety notice and the share move has been established.
Guidance Raised, Operating Profit Diverges
The label news lands alongside a busier corporate calendar. On 4 November Novo Nordisk lifted its forecasts for adjusted revenue growth and adjusted operating profit growth. For 2026 it projects a range of ?2% to +2% for each measure at constant exchange rates.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Third-quarter 2026 adjusted operating profit rose 27% at constant currencies, reaching DKK 31.7 billion. Reported operating profit moved the other way, falling 9% on the same basis, after absorbing non-cash impairment charges of DKK 8.7 billion.
Novo also released a post-hoc analysis of the ESSENCE trial of semaglutide on Sunday. The review covered a subgroup of 106 adults with MASH and liver scarring whose body mass index was below 27. According to the company, measures of liver damage, disease activity and fibrosis fared better than with placebo. Novo explicitly described the exploratory analysis as hypothesis-generating.
Washington Beckons
Attention now shifts to ObesityWeek, running 14–17 November in Washington, D.C., where Novo has flagged further presentations. Data from across its obesity portfolio are on the agenda, including CagriSema and Wegovy.
Ad
Novo Nordisk Stock: New Analysis - 10 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
